Worldwide reported use of IV tissue plasminogen activator for acute ischemic stroke

International Journal of Stroke

Volumn 9, Issue 3, 2014, Pages 349-355

  Berkowitz, Aaron L ^a   Mittal, Manoj K ^b   Mclane, Hannah C ^c   Shen, Gordon C ^d   Muralidharan, Rajanandini ^e   Lyons, Jennifer L ^a   Shinohara, Russell T ^f   Shuaib, Ashfaq ^g   Mateen, Farrah J ^a,h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF ALBERTA   (Canada)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Epidemiology; Global health; Stroke; Thrombolysis

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

BRAIN ISCHEMIA; DISABILITY; DRUG USE; HEALTH CARE COST; HUMAN; INFORMATION RETRIEVAL; LOWEST INCOME GROUP; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

EPIDEMIOLOGY; GLOBAL HEALTH; STROKE; THROMBOLYSIS;

ADMINISTRATION, INTRAVENOUS; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; WORLD HEALTH;

EID: 84896314015     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12205     Document Type: Review

References (38)

1. Lozano R, Naghavi M, Foreman K etal. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095-2128.
2. Murray CJ, Vos T, Lozano R etal. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197-2223.
3. Feigin VL. Stroke in developing countries: can the epidemic be stopped and outcomes improved. Lancet Neurol 2007; 6:94-97.
4. No authors listed. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581-1587.
5. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet 2007; 5:182-187.
6. Pandian JD, Padma V, Vijaya P, Sylaja PN, Murthy JMK. Stroke and thrombolysis in developing countries. Int J Stroke 2007; 2:17-26.
7. Barber M, Langhorne P, Stott DJ. Barriers to delivery of thrombolysis for acute stroke. Age Ageing 2004; 33:94-95.
8. Eissa A, Krass I, Bajorek BV. Barriers to the utilization of thrombolysis for acute ischemic stroke. J Clin Pharm Ther 2012; 37:399-409.
9. Ghandehari K. Barriers of thrombolysis therapy in developing countries. Stroke Res Treat 2011; 2011:686797.
10. Engelter ST, Gostynski M, Papa S, Ajdacic-Gross V, Lyrer PA. Barriers to stroke thrombolysis in a geographically defined population. Cerebrovasc Dis 2007; 23:211-215.
11. World Bank. Data: how we classify countries. Available at http://data.worldbank.org/about/country-classifications (accessed 16 February 2013).
12. World Health Organization. Data and statistics: countries. Available at http://www.who.int/countries/en/ (accessed 16 February 2013).
13. World Health Organization. Department of Measurement and Health Information.Global burden of disease. Available at http://www.who.int/healthinfo/global_burden_disease/gbddeathdalycountryestimates2004.xls ( accessed 16 February 2013).
14. Stroup DF, Berlin JA, Morton SC etal. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-2012.
15. Yusuf S, Islam S, Chow CK etal. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378:1231-1243.
16. Schmülling S, Grond M, Jobst R, Heiss W. One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke 2000; 30:1552-1554.
17. Schneider AT, Pancioli AM, Khoury JC etal. Trends in community knowledge of the warning signs and risk factors for stroke. JAMA 2003; 289:343-346.
18. Langhorne P, de Villiers L, Pandian JD. Applicability of stroke-unit care to low-income and middle-income countries. Lancet Neurol 2012; 11:341-348.
19. Müller-Barna P, Schwamm LH, Haberl RL. Telestroke increases use of acute stroke therapy. Curr Opin Neurol 2012; 25:5-10.
20. Ghandehari K, Foroughipour M, Pourzahed A etal. Thrombolysis in stroke patients: problems and limitations. Iran J Med Sci 2010; 35:145-148.
21. Pandian JD, Sethi V, Dhillon R etal. Is intravenous thrombolysis feasible in a developing country. Cerebrovas Dis 2005; 20:134-136.
22. Nandigam K, Narayan SK, Elangovan S, Dutta TK, Sethuraman KR, Das AK. Feasibility of acute thrombolytic therapy for stroke. Neurol India 2003; 51:470-473.
23. Pandian JD, Srikanth V, Read SJ, Thrift AG. Poverty and stroke in India: a time to act. Stroke 2007; 38:3063-3069.
24. Wassay M, Barohi H, Malik A, Yousuf A, Awan S, Kamal AK. Utilization and outcome of thrombolytic therapy for acute stroke in Pakistan. Neurol Sci 2010; 31:223-225.
25. Nguyen TH, Truong AT, Ngo MB etal. Intravenous thrombolysis. Int J Stroke 2010; 5:514-518.
26. Guinhouya KM, Tall A, Kombate D etal. [Cost of stroke in Lomé (Togo).]. Sante 2010; Aug. 4, PMID: 20682484.
27. World Health Organization & World Federation of Neurology. Atlas: Country Resources for Neurological Disorders. Geneva, World Health Organization, 2004.
28. El Khamlichi A. African neurosurgery: current situation, priorities, and needs. Neurosurgery 2001; 48:1344-1347.
29. Brainin M, Teuschl Y, Kalra L. Acute treatment and long-term management of stroke in developing countries. Lancet Neurol 2007; 6:553-561.
30. Akinyemi RO, Ogah OS, Ogunidpe RF etal. Knowledge and perception of stroke amongst hospital workers in an African community. Eur J Neurol 2009; 16:998-1003.
31. Mateen FJ, Carone M, Alam N, Streatfield PK, Black RE. A population-based case-control study of 1250 stroke deaths in rural Bangladesh. Eur J Neurol 2012; 19:999-1006.
32. Engelter ST, Gostynski M, Papa S, Ajdacic-Gross-V LPA. Barriers to stroke thrombolysis in a geographically defined population. Cerebrovasc Dis 2007; 23:211-215.
33. Fagan SC, Morgenstern LB, Petitta A etal. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA stroke study group. Neurology 1998; 50:883-890.
34. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke 2005; 36:2500-2503.
35. Sinclair SE, Frighetto L, Loewen PS etal. Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 2001; 19:927-936.
36. Chaisam T, Suwanwela NC, Phanthumchinda K. Cost-effectiveness of recombinant tissue plasminogen activator for acute ischemic stroke [abstract]. Abstracts of the 6th World Stroke Congress and Xth International Symposium on Thrombolysis and Acute Stroke Therapy, 24-27 September 2008 Vienna, Austria and 21-23 September 2008, Budapest, Hungary. Int J Stroke 2008; 3(Suppl 1):267. P002-27.
37. Shahtaheri RA, Haghighi AB, Safari A, Cruz-Flores S. Recombinant tissue plasminogen activator (rtPA) and stroke unit for acute ischaemic stroke in developing countries, are they cost-effective. Int J Stroke 2012; 7:e9.
38. Feigin VL, Lawes CM, Bennett DA, Barker-Collo S, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009; 8:355-369.